Catalyst Brief

← Calendar

Readoutin 165d

Merck Sharp & Dohme LLC — Sacituzumab tirumotecan

Phase 3 primary completion: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004).

Date
May 2027
Type
Readout
Indication
Non-small Cell Lung Cancer (NSCLC)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merck Sharp & Dohme LLC

  1. May2027
  2. Jan2027
  3. Jan2027
  4. Nov2026